Thymopentin with oncolytic adenovirus in mouse tumor models
Animal research · 2026
- What was studied
- 4T1 breast, CT26 colorectal and H22 liver tumor models in mice. Main comparisons used 6–8 mice per 4T1 arm, 9 per CT26 arm and 8 per H22 arm. The patient-derived breast tumor xenograft experiment used 5 mice per group.
- Main finding
- H22 liver tumor response and rechallenge · The authors observed tumor regression by day 35 in the combination group. Selected mice that had cleared H22 tumors resisted H22 rechallenge but developed 4T1 tumors after a separate challenge.
Reported findings and study design
Reported findings
Mouse arms compared saline, thymopentin, oncolytic adenovirus, and their combination. Adenovirus was given into the tumor at 2 × 10⁸ plaque-forming units every other day for three injections. Thymopentin was injected subcutaneously near the tumor daily. Additional experiments tested an engineered virus that expressed the peptide.
Population or model 4T1 breast, CT26 colorectal and H22 liver tumor models in mice. Main comparisons used 6–8 mice per 4T1 arm, 9 per CT26 arm and 8 per H22 arm. The patient-derived breast tumor xenograft experiment used 5 mice per group.
Dose, route and schedule
Mouse arms compared saline, thymopentin, oncolytic adenovirus, and their combination. Adenovirus was given into the tumor at 2 × 10⁸ plaque-forming units every other day for three injections. Thymopentin was injected subcutaneously near the tumor daily. Additional experiments tested an engineered virus that expressed the peptide.
Protocol source ↗ · Original full text, including study methods and Figures 1–5 and 7.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| H22 liver tumor response and rechallenge | The authors observed tumor regression by day 35 in the combination group. Selected mice that had cleared H22 tumors resisted H22 rechallenge but developed 4T1 tumors after a separate challenge. | |
| Immune-cell dependence | The combination increased cytotoxic CD8-positive T-cell and proinflammatory macrophage infiltration. Depletion of either cell population weakened the tumor response. | |
| Engineered adenovirus | The thymopentin-expressing virus slowed tumor growth and prolonged survival in mouse experiments. The two viruses had similar replication and cell-killing behavior in the tested cell cultures. |
All treatment experiments were preclinical, including experiments that used human tumor tissue grafted into mice. The main methods specify the injection frequency for free thymopentin without giving a mass dose. The rechallenge used selected mice that had already cleared tumors.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- All treatment experiments were preclinical, including experiments that used human tumor tissue grafted into mice. The main methods specify the injection frequency for free thymopentin without giving a mass dose. The rechallenge used selected mice that had already cleared tumors.
Source details
Original full text, including study methods and Figures 1–5 and 7.
Sources checked
Added to the library
Citation
L. Kong, K. Liu, Y. Liu, H. Cui, P. Wang, J. Qiu, Q. Xin, D. Zhou, W. Liu, F. Zhao, J. Wu, X. Gu, J. Wu, C. Jiang. Thymopentin with oncolytic adenovirus in mouse tumor models Communications Medicine 6, article 265
Study source ↗ · DOI 10.1038/s43856-026-01509-6 · Bibliography entry · Link to this summary